Age-related differences in 1p and 19q deletions in oligodendrogliomas
1 Molecular Diagnostic Pathology Laboratory, Department of Pathology, Health Sciences Centre, 820 Sherbrook St, Winnipeg, Manitoba, Canada, R3A 1A9
2 Neuropathology Section, Department of Pathology, Health Sciences Centre, 820 Sherbrook St, Winnipeg, Manitoba, Canada, R3A 1A9
3 Department of Pathology, University of Manitoba, 770 Bannatyne Ave., Winnipeg, Manitoba, Canada R3E 0W3
Citation and License
BMC Clinical Pathology 2003, 3:6 doi:10.1186/1472-6890-3-6Published: 11 December 2003
Recent reports indicate that anaplastic oligodendrogliomas frequently show allelic losses on chromosome arms 1p and 19q, and that these deletions are associated with better chemotherapeutic response and overall patient survival. Because of the diversified genetic makeup of the population and the centralized provincial referral system for brain tumor patients in Manitoba, the epidemiological features of such tumors sometimes differ from the published data acquired from non-community based settings. In this study, we assessed the prevalence of allelic deletions for chromosome arms 1p and 19q in anaplastic and in low-grade oligodendrogliomas in the Manitoba population.
Loss of heterozygosity (LOH) analysis of brain tumors was carried out using 4 microsatellite markers (D1S508, D1S2734, D19S219 and D19S412) and a PCR based assay. The tumors were consecutively acquired during the period September 1999–March 2001 and a total of 63 tumors were assessed.
We found that allelic loss of chromosome 1p and 19q was higher in oligodendrogliomas than in other diffuse gliomas and that for anaplastic oligodendrogliomas, younger patients exhibited significantly more deletions than older patients (>60 years of age).
These studies suggest that age may be a factor in the genetic alterations of oligodendrogliomas. In addition, these studies demonstrate that this assay can easily be carried out in a cost-effective manner in a small tertiary center.